531686 ADVIKLA

MPS Pharma Share Price

₹4.25 +0.12 (2.91%)

29 Dec, 2024 06:19

SIP TrendupStart SIP in ADVIKLA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 2.91%
  • Over 3 Month + 6.52%
  • Over 6 Month + 21.78%
  • Over 1 Year + 52.33%
SIP Lightning

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹4.25
+ 0.12 (2.91%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹3.93
  • 50 Day
  • ₹3.50
  • 100 Day
  • ₹2.95
  • 200 Day
  • ₹2.41

Resistance and Support

4.18 Pivot Speed
  • R3 4.84
  • R2 4.58
  • R1 4.44
  • S1 4.04
  • S2 3.78
  • S3 3.64

What's your outlook on MPS Pharma?

You can only vote for once

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-03-26 Independent Director Meeting
2024-02-13 Quarterly Results

MPS Pharma F&O

MPS Pharma Shareholding Pattern

No data available.

About MPS Pharma

  • NSE Symbol
  • ADVIKLA
  • BSE Symbol
  • 531686
  • ISIN
  • INE537C01019

Similar Stocks to MPS Pharma

MPS Pharma FAQs

MPS Pharma share price is ₹4 As on 29 December, 2024 | 06:05

The Market Cap of MPS Pharma is ₹8.1 Cr As on 29 December, 2024 | 06:05

The P/E ratio of MPS Pharma is -9 As on 29 December, 2024 | 06:05

The PB ratio of MPS Pharma is 4.1 As on 29 December, 2024 | 06:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23